SAN FRANCISCO — A 6-month course of oral valganciclovir improves hearing and nerve development in infants with cytomegalovirus, and works better than a 6-week course, report researchers. This is the ...

The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over ...

Learn everything you need to know about Valganciclovir-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Valganciclovir is an orally administered prodrug that is rapidly hydrolyzed to ganciclovir. We compared the effects of oral valganciclovir with those of intravenous ganciclovir as induction therapy ...

On September 15, 2003, the US Food and Drug Administration changed the indications for valganciclovir (Valcyte) to include prevention of CMV disease in kidney, pancreas, and heart transplant patients.

Review the side-effects of Valganciclovir as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The monoclonal anti-CD52 antibody alemtuzumab is active against chronic lymphocytic leukemia and other low-grade B- and T-cell lymphoproliferative diseases. It is lymphoablative, making patients ...

Andre Kalil, MD VANCOUVER, British Columbia—Half of the approved dose for cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients is just as effective as the approved dose and is safer, ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to nanatinostat and valganciclovir for treatment of Epstein Barr ...

Plus new oral solution offers dosing flexibility for pediatric patients Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte ...

All consecutive patients undergoing MA and reduced-intensity allogeneic stem cell transplantation at the Leiden University Medical Center between January 2001 and December 2004 were included in this ...